{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:49:59Z","timestamp":1780494599997,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Programmed death ligand-1 (PD-L1), anaplastic lymphoma kinase (ALK), and c-ros oncogene1 (ROS1) expression may influence the prognosis of non-small cell lung carcinoma (NSCLC). We aimed to investigate the prognostic and predictive significance of PD-1\/PD-L1 along with c-ros ROS1 and ALK in NSCLC patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Immunohistochemistry used to identify ALK, ROS1, PD-1, and PD-L1 proteins expression as well as <jats:italic>ROS1<\/jats:italic> rearrangement via fluorescence in situ hybridization, in 70 NSCLC patients. Results were related to clinicopathological feature, survival, and treatment response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Expression of ROS1, ALK, PD-1, and PD-L1 and ROS1-rearrangement were detected in 18.57%, 54.29%, 84.29%, 87.14%, and 15.71% of the cases, respectively. No association was found between ROS1, PD-1, and PD-L1 and any clinicopathological features, survival, or treatment outcome. ALK expression significantly associated with stage-IV and left-sided tumors. Epidermal growth factor receptor <jats:italic>(EGFR)<\/jats:italic> mutation and ALK-positive patients had significantly reduced progression-free survival than patients with wild type EGFR [HR: 1.99, 95% CI: 1.37\u20132.93, <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.001] and negative-ALK expression [HR: 1.46, 95% CI: 1.03\u20132.07, <jats:italic>p<\/jats:italic>\u00a0=\u20090.03]. In multivariate analysis, lymph node metastasis, <jats:italic>EGFR<\/jats:italic>-mutations, and ALK were independent predictors of NSCLC. PD-L1 expression was significantly correlated with PD-1 but not with ROS1, ALK, or <jats:italic>EGFR-<\/jats:italic>mutation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Positive ALK expression and <jats:italic>EGFR<\/jats:italic>-mutations are independent adverse predictors of NSCLC. Overexpression of PD-1\/PD-L1 is not a significant prognostic marker in NSCLC patients receiving chemotherapy, making them susceptible to immunotherapy. Since PD-1\/PD-L1 expression is independent to oncogenic driver mutations, future studies into specific immune checkpoint inhibitors combined with targeted therapies for individualized treatment of NSCLC is warranted.<\/jats:p>\n                <jats:p>Positive ALK expression and EGFR mutations are independent risk factors for NSCLC. Overexpression of PD-1\/PD-L1 is not a significant prognostic factor in patients with NSCLC who are receiving chemotherapy, making them immunotherapy susceptible. Given that PD-1\/PD-L1 expression is not dependent on oncogenic driver mutations, additional research into specific immune checkpoint inhibitors in combination with targeted therapies for the treatment of NSCLC on an individual basis is warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43046-022-00121-8","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:02:15Z","timestamp":1653868935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt"],"prefix":"10.1186","volume":"34","author":[{"given":"Abeer A.","family":"Bahnassy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Mohanad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"El-Bastawisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hend F.","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"issue":"1","key":"121_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"121_CR2","first-page":"89","volume":"2","author":"W Shao","year":"2010","unstructured":"Shao W, Wang D, He J. The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis. 2010;2(2):89\u201399.","journal-title":"J Thorac Dis"},{"issue":"8","key":"121_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735\u201342.","journal-title":"Lancet Oncol"},{"issue":"3","key":"121_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321\u201346.","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"121_CR5","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jtho.2016.12.026","volume":"12","author":"D Rangachari","year":"2017","unstructured":"Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, et al. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 \u226550% expression in lung adenocarcinoma. J Thorac Oncol. 2017;12(5):878\u201383.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"121_CR6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1097\/JTO.0b013e31826baf83","volume":"7","author":"LP Chin","year":"2012","unstructured":"Chin LP, Soo RA, Soong R, Ou SH. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol. 2012;7(11):1625\u201330.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"121_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.trecan.2016.05.010","volume":"2","author":"JJ Lin","year":"2016","unstructured":"Lin JJ, Shaw AT. Resisting resistance: targeted therapies in lung cancer. Trends Cancer. 2016;2(7):350\u201364.","journal-title":"Trends Cancer"},{"key":"121_CR8","doi-asserted-by":"crossref","unstructured":"Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, Hernandez C, Fernandez G, et al. Resistance to PD-L1\/PD-1 blockade immunotherapy. A tumor-intrinsic or tumor-extrinsic phenomenon? Front Pharmacol. 2020;11:441.","DOI":"10.3389\/fphar.2020.00441"},{"key":"121_CR9","doi-asserted-by":"crossref","first-page":"175883401774501","DOI":"10.1177\/1758834017745012","volume":"10","author":"I Moya-Horno","year":"2018","unstructured":"Moya-Horno I, Viteri S, Karachaliou N, Rosell R. Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Therapeut Adv Med Oncol. 2018;10:1758834017745012.","journal-title":"Therapeut Adv Med Oncol"},{"issue":"1","key":"121_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jtho.2016.08.137","volume":"12","author":"M Wiesweg","year":"2017","unstructured":"Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, et al. High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer. J Thorac Oncol. 2017;12(1):54\u201364.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"121_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/ijmr.IJMR_1221_15","volume":"146","author":"R Walia","year":"2017","unstructured":"Walia R, Jain D, Madan K, Sharma MC, Mathur SR, Mohan A, et al. p40 & thyroid transcription factor-1 immunohistochemistry: a useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category. Indian J Med Res. 2017;146(1):42.","journal-title":"Indian J Med Res"},{"issue":"1","key":"121_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39\u201351.","journal-title":"J Thorac Oncol"},{"key":"121_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-update and clarification: From the RECIST committee. Eur J Cancer (Oxford, England : 1990). 2016;62:132\u20137.","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"1","key":"121_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1186\/s13063-020-04745-w","volume":"21","author":"LM Wintner","year":"2020","unstructured":"Wintner LM, Giesinger JM, Sztankay M, Bottomley A, Holzner B. on behalf of the EQoLG. Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial. Trials. 2020;21(1):849.","journal-title":"Trials."},{"key":"121_CR15","doi-asserted-by":"crossref","unstructured":"Sholl LM, Sun H, Butaney M, Zhang C, Lee C, J\u00e4nne PA, et al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol. 2013;37(9):1-37.","DOI":"10.1097\/PAS.0b013e3182960fa7"},{"issue":"4","key":"121_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/JTO.0000000000000427","volume":"10","author":"K Gruber","year":"2015","unstructured":"Gruber K, Kohlh\u00e4ufl M, Friedel G, Ott G, Kalla C. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry. J Thorac Oncol. 2015;10(4):713\u20136.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"121_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jasc.2018.02.003","volume":"7","author":"VF Torous","year":"2018","unstructured":"Torous VF, Rangachari D, Gallant BP, Shea M, Costa DB, VanderLaan PA. PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non\u2013small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol. 2018;7(3):133\u201341.","journal-title":"J Am Soc Cytopathol"},{"issue":"4","key":"121_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.21037\/tlcr.2019.08.04","volume":"8","author":"H Li","year":"2019","unstructured":"Li H, Xu Y, Wan B, Song Y, Zhan P, Hu Y, et al. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. Translat Lung Cancer Res. 2019;8(4):429\u201349.","journal-title":"Translat Lung Cancer Res"},{"key":"121_CR19","first-page":"39","volume":"28","author":"KM Mahoney","year":"2014","unstructured":"Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park). 2014;28:39\u201348.","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"121_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.tranon.2016.01.003","volume":"9","author":"SF Sorensen","year":"2016","unstructured":"Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K, et al. PD-L1 Expression and survival among patients with advanced non\u2013small cell lung cancer treated with chemotherapy. Translat Oncol. 2016;9(1):64\u20139.","journal-title":"Translat Oncol"},{"issue":"1","key":"121_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/bjc.2014.555","volume":"112","author":"A D'Incecco","year":"2015","unstructured":"D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112(1):95\u2013102.","journal-title":"Br J Cancer"},{"issue":"3","key":"121_CR22","first-page":"774","volume":"12","author":"Q Chen","year":"2019","unstructured":"Chen Q, Fu Y-Y, Yue Q-N, Wu Q, Tang Y, Wang W-Y, et al. Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer. Int J Clin Exp Pathol. 2019;12(3):774\u201386.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"121_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.lungcan.2015.01.016","volume":"88","author":"M-Y Kim","year":"2015","unstructured":"Kim M-Y, Koh J, Kim S, Go H, Jeon YK, Chung DH. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer. 2015;88(1):24\u201333.","journal-title":"Lung Cancer"},{"issue":"7","key":"121_CR24","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","volume":"11","author":"H Yu","year":"2016","unstructured":"Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 expression in lung cancer. J Thorac Oncol. 2016;11(7):964\u201375.","journal-title":"J Thorac Oncol"},{"key":"121_CR25","doi-asserted-by":"crossref","unstructured":"Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis. Medicine. 2015;94(6):e515.","DOI":"10.1097\/MD.0000000000000515"},{"issue":"2","key":"121_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.lungcan.2015.06.005","volume":"4","author":"Z-J Zhou","year":"2015","unstructured":"Zhou Z-J, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Translat Lung Cancer Res. 2015;4(2):203.","journal-title":"Translat Lung Cancer Res"},{"key":"121_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejca.2019.10.019","volume":"124","author":"C-Y Yang","year":"2020","unstructured":"Yang C-Y, Liao W-Y, Ho C-C, Chen K-Y, Tsai T-H, Hsu C-L, et al. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur J Cancer. 2020;124:110\u201322.","journal-title":"Eur J Cancer"},{"issue":"11","key":"121_CR28","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.jtho.2017.08.002","volume":"12","author":"JJ Lin","year":"2017","unstructured":"Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer. J Thorac Oncol. 2017;12(11):1611\u201325.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"121_CR29","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1097\/JTO.0000000000000232","volume":"9","author":"Y-F Chen","year":"2014","unstructured":"Chen Y-F, Hsieh M-S, Wu S-G, Chang Y-L, Shih J-Y, Liu Y-N, et al. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. J Thorac Oncol. 2014;9(8):1171\u20139.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"121_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.lungcan.2013.11.019","volume":"83","author":"L Mescam-Mancini","year":"2014","unstructured":"Mescam-Mancini L, Lantu\u00e9joul S, Moro-Sibilot D, Rouquette I, Souquet P-J, Audigier-Valette C, et al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer. 2014;83(2):168\u201373.","journal-title":"Lung Cancer"},{"issue":"1","key":"121_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1245\/s10434-012-2553-6","volume":"20","author":"HJ Lee","year":"2013","unstructured":"Lee HJ, Seol HS, Kim JY, Chun SM, Suh YA, Park YS, et al. ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms. Ann Surg Oncol. 2013;20(1):200\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"121_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/1759-7714.12191","volume":"6","author":"S Wu","year":"2015","unstructured":"Wu S, Wang J, Zhou L, Su D, Liu Y, Liang X, et al. Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements. Thorac Cancer. 2015;6(4):413\u201320.","journal-title":"Thorac Cancer"},{"issue":"10","key":"121_CR33","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.21037\/jtd.2017.09.79","volume":"9","author":"Z Song","year":"2017","unstructured":"Song Z, Zheng Y, Wang X, Su H, Zhang Y, Song Y. ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases. J Thorac Dis. 2017;9(10):3919.","journal-title":"J Thorac Dis"},{"issue":"3","key":"121_CR34","first-page":"3466","volume":"17","author":"YC Zhu","year":"2019","unstructured":"Zhu YC, Zhang XG, Lin XP, Wang WX, Li XF, Wu LX, et al. Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1-positive non-small cell lung cancer. Oncol Lett. 2019;17(3):3466\u201374.","journal-title":"Oncol Lett"},{"issue":"3","key":"121_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120422","volume":"10","author":"L Shan","year":"2015","unstructured":"Shan L, Lian F, Guo L, Qiu T, Ling Y, Ying J, et al. Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR. PLoS One. 2015;10(3):e0120422.","journal-title":"PLoS One"},{"issue":"10","key":"121_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110617","volume":"9","author":"Y Wang","year":"2014","unstructured":"Wang Y, Wang S, Xu S, Qu J, Liu B. Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis. PLoS One. 2014;9(10):e110617.","journal-title":"PLoS One"},{"issue":"9","key":"121_CR37","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00432-019-02978-0","volume":"145","author":"M Ito","year":"2019","unstructured":"Ito M, Miyata Y, Hirano S, Kimura S, Irisuna F, Ikeda K, et al. Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma. J Cancer Res Clin Oncol. 2019;145(9):2325\u201333.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-022-00121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-022-00121-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-022-00121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:02:32Z","timestamp":1653868952000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-022-00121-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["121"],"URL":"https:\/\/doi.org\/10.1186\/s43046-022-00121-8","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]},"assertion":[{"value":"22 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by institutional Review Board of National Cancer Institute (NCI), Cairo, Egypt, as guided by the 2013 Helsinki Declaration. Written informed consent forms were obtained from each patient for sampling and research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}